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S U M M A R Y
Crohn’s disease is associated with treatment and non-treatment infectious complications. Among the
treatment-related infectious complications, Histoplasma infection is interesting because of signiﬁcant
overlap between its symptoms and Crohn’s disease exacerbation. It is often mistaken as Crohn’s disease
exacerbation. We present a case of disseminated histoplasmosis presenting as Histoplasma epiglottitis
in a patient with Crohn’s disease maintained on inﬂiximab, prednisone, and azathioprine.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crohn’s disease is associated with many treatment-related and
non-treatment-related complications. Some of the infectious
complications include opportunistic infections, mostly in associa-
tion with the use of immunosuppressive medications in the
treatment of Crohn’s disease. Disseminated histoplasmosis is
uncommon in immunocompetent patients, although it is not
uncommon in immunosuppressed patients, such as those on
treatment for Crohn’s disease. Among those with disseminated
histoplasmosis, otolaryngologic involvement as a focus for
Histoplasma dissemination is extremely rare, limited to case
reports. We hereby report the ﬁrst case report of disseminated
histoplasmosis due to Histoplasma epiglottitis in a Crohn’s disease
patient on inﬂiximab, prednisone, and azathioprine.
2. Case report
A 43-year-old man with Crohn’s disease maintained on
azathioprine, prednisone, and inﬂiximab for the last 18 months,
presented to the clinic with worsening odynophagia, hoarseness,* Corresponding author. Tel.: +1 214 857 1588; Fax: +1 214 857 1575.
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http://dx.doi.org/10.1016/j.ijid.2013.02.021and fever of over 3 months duration. He denied any pulmonary
symptoms. His past medical history was otherwise negative. He
lives in Dallas and denied any recent travel. Initial work-up
included esophogastroduodenoscopy (EGD), which showed an
edematous and erythematous epiglottis. The patient was managed
as a case of Crohn’s disease exacerbation. His immunosuppression
regimen was increased from inﬂiximab (Remicade) 10 mg/kg
every 8 weeks to 10 mg/kg every 6 weeks. Prednisone had been
titrated up over the last 3 months prior to presentation to 40 mg
per day, and azathioprine was increased to 400 mg per day.
However his symptoms continued to worsen. Additional work-up
included a computed tomography (CT) scan of the neck, which
showed nodular thickening of the epiglottis and aryepiglottic
(Figure 1A). Laryngoscopy showed an exophytic lesion arising
from the edge of the epiglottis with extension to the laryngeal
surface of the epiglottis and to the left aryepiglottic fold. In
the interim period while the biopsy result was pending, the
patient’s symptoms continued to worsen, and he presented to
our facility with dehydration. On admission the patient was
in no distress. He was febrile to 39.0 8C, with a heart rate of
110 beats/min, a blood pressure of 129/82 mmHg, and a
respiratory rate of 16 breaths/min. Otherwise the remainder of
his physical examination was normal. Laboratory results were
signiﬁcant for a leukocyte count of 2.5  109/l, hemoglobin of
12.1 g/dl, and an erythrocyte sedimentation rate (ESR) of 41 mm/h.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. (A) CT scan of the neck showing an inﬂamed epiglottis. (B) Biopsy showing budding yeast and features consistent with Histoplasma capsulatum.
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infection (Figure 1B). Histoplasma antibodies and urine antigen
were negative. Serum Histoplasma antigen was positive (6.17 ng/
ml) and fungal cultures were positive for Histoplasma capsulatum.
The ﬁnal diagnosis was disseminated histoplasmosis presenting as
epiglottitis. The patient’s immunosuppressive regimen was
tapered down (inﬂiximab and azathioprine were stopped and
prednisone was tapered down). The patient was initially started on
amphotericin and then itraconazole, with rapid improvement in
his symptoms. However, several weeks after tapering down his
immunosuppressive regimen the patient presented with a Crohn’s
disease ﬂare manifesting as gastrointestinal bleeding, so azathio-
prine was reinitiated.
3. Discussion
Crohn’s disease is associated with signiﬁcant infectious com-
plications, both treatment- and non-treatment related. The odds of
developing opportunistic infections are increased by three times
with the use of immunosuppressive drugs that include azathio-
prine, inﬂiximab, and steroids individually and by 14 times when
used in combination.1 Among these infections, disseminated
histoplasmosis is interesting because its presentation can mimic
Crohn’s disease exacerbations. Disseminated histoplasmosis is
caused by a dimorphic fungus that grows as mold at temperatures
less than 35 8C and as yeast at temperatures above that. Endemic
areas in the USA include river valleys in the mid-western and
southeastern states. It is an inhalation-acquired mycosis in most of
the cases. Dissemination can be acute or can occur years after the
initial exposure. Disseminated infection is uncommon in immuno-
competent patients. However it is common in immunosuppressed
patients.2 Data regarding fungal infections in inﬂammatory bowel
disease (IBD) patients maintained on immunosuppressive agents,
including inﬂiximab, are limited to case reports and case series. Two
hundred forty cases of histoplasmosis associated with tumor
necrosis factor alpha (TNF-a) inhibitors had been reported to the
Adverse Event Reporting System (AERS) as of September 2008.
Pneumonia was the most common clinical manifestation.3
Clinically disseminated histoplasmosis can present with fever
(91%), cough (65%), hepatosplenomegaly or lymphadenopathy
(52%), weight loss (48%), and anemia (39%).2 Of the patients with
disseminated histoplasmosis, 70–90% have gastrointestinal in-
volvement.4 The gastrointestinal symptoms include nausea,
vomiting, diarrhea, bleeding, abdominal pain, weight loss,
obstruction, and perforation. The most frequently involved sitesare the terminal ileum and cecum.4 Many of these symptoms
overlap with Crohn’s disease exacerbation. Also there is signiﬁcant
overlap among the endoscopic ﬁndings that include plaques, small
polyps, mucosal edema, ulcerations, strictures, and masses.4
Laryngeal and oropharyngeal involvement is commonly described
in disseminated Histoplasma (66% with chronic progressive
disseminated histoplasmosis (PDH) and 31% in subacute PDH).
However isolated epiglottic histoplasmosis is rare. In a series of 29
patients with acute, subacute, and chronic PDH, only a single case
of epiglottic involvement out of 58 cases with otolaryngologic
involvement was reported.2 O’Hara et al. described a case of
epiglottic histoplasmosis in an immunocompetent man presenting
as an irregular mass with ulceration on the free edge of the
epiglottis.2
This case presented a diagnostic challenge because of the
patient’s presentation with isolated epiglottic histoplasmosis and
the overlap of his presentation with possible Crohn’s disease ﬂare.
The differential diagnosis includes Crohn’s disease ﬂare, infections
including histoplasmosis, blastomycosis, and tuberculosis, and
malignancy. It is very important to recognize infectious etiologies
including histoplasmosis because immunosuppressive treatments
of Crohn’s disease ﬂare can worsen them. In this case there were
several clinical clues that hinted at an infectious etiology. The
patient did not have symptoms of Crohn’s disease ﬂare elsewhere,
as he usually has. Another important clue was that his symptoms
became worse after the escalation of the immunosuppressive
regimen, which is unusual for Crohn’s ﬂares. Corticosteroids
usually result in an 80–90% response rate among patients with
moderate to severe disease, and inﬂiximab result in a 50–80%
response rate in refractory cases.4 Histoplasmosis in the upper
aerodigestive tract may mimic tuberculosis. However, tuberculosis
usually involves the posterior larynx and it rarely involves the
epiglottis. Laryngeal tuberculosis is also rarely associated with
oropharyngeal ulcers.2
Currently, screening for fungal infections in IBD patients prior
to initiation of immunosuppressive agents is not indicated.
However, a high index of suspicion is needed in patients with
worsening symptoms despite being on multiple immunosuppres-
sive agents. A multifaceted diagnostic work-up should be initiated.
Diagnosis starts with histopathology (using methenamine silver or
periodic acid Schiff stains) usually demonstrating 2–4 m yeast
structures. Blood cultures should be sent. Blood cultures are
usually positive in 50–70% of the cases of disseminated histoplas-
mosis. Antigen testing in both urine and blood should be done in all
cases of suspected disseminated histoplasmosis. Urine antigen is
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approximately 90% of cases. Though serological tests for anti-
Histoplasma antibodies can be false-negative in 20% of patients
taking TNF inhibitors, they are still recommended.5
Once the infection is identiﬁed, steroids should be tapered.
Anti-TNF-a treatment should be stopped. There are no data
regarding the safety of reintroducing TNF-a blockers after the
completion of Histoplasma treatment. Antifungal therapy with
amphotericin or itraconazole, depending on disease severity,
should be considered.
Cases such as this present both diagnostic and management
challenges. The signiﬁcant overlap between Histoplasma infec-
tions and Crohn’s disease exacerbations presents a diagnostic
challenge. The management challenges include by how much to
decrease or stop immunosuppression and when to reinitiate it.Conﬂict of interest: All authors declare no ﬁnancial or personal
relationships with other people or organizations that could
inappropriately inﬂuence the manuscript content.
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